Kapa Biosystems Launches New RNA Prep Kit To Maximize Sequencing Efficiency

WILMINGTON, Mass.--(BUSINESS WIRE)--Kapa Biosystems, Inc., today launched a new RNA library preparation product for next-generation sequencing (NGS) workflows that enables users to generate a more complete view of the transcriptome by detecting more low-abundance and unique transcripts. The KAPA Stranded RNA-Seq Kit with RiboErase uses a targeted enzymatic depletion method to remove ribosomal RNA (rRNA) and thereby improve sequencing efficiency.

“Transcriptome analysis is critical to understanding gene function and its downstream effects on phenotype”

In RNA library preparation, even small amounts of residual rRNA can dramatically reduce sequencing efficiency and data quality. Using enzymatic depletion, the KAPA Stranded RNA-Seq Kit with RiboErase reduces rRNA at industry-leading rates of 99.98 percent. The kit provides an alternative to mRNA enrichment, since rRNA depletion allows for the analysis of exonic regions, precursor mRNAs, and long non-coding RNAs.

“Transcriptome analysis is critical to understanding gene function and its downstream effects on phenotype,” said Deepti Sanjai, Global Product Manager for NGS at Kapa Biosystems. “This kit is an exciting addition to our NGS portfolio for RNA-Seq, providing Kapa customers with a highly sensitive and accurate means of interrogating gene expression that offers significant performance advantages compared to competitive offerings.”

The KAPA Stranded RNA-Seq Kit with RiboErase is available for use with human, mouse, and rat samples and is robust and reproducible with flexible input amounts. Kits also contain a low-bias engineered enzyme called KAPA HiFi, a low-bias engineered enzyme, for maximum coverage uniformity, and include a streamlined, “with-bead” protocol. The kit is supported for use on Illumina sequencing systems. More information about the new kit is available here.

About Kapa Biosystems

Kapa Biosystems is a life science reagents supplier that employs proprietary, directed-evolution technologies to optimize enzymes for next-generation sequencing applications as well as PCR and real-time PCR. Kapa Biosystems offers a portfolio of best-in-class products containing novel enzymes that confer significant performance advantages when compared to traditional wild-type enzymes. The company is based in Wilmington, Massachusetts, with a research, development, and manufacturing facility in Cape Town, South Africa. For more information, please visit www.kapabiosystems.com.

KAPA is a trademark of Kapa Biosystems.

Kapa Biosystems’ products are for Research Use Only; not for use in diagnostic procedures.